(Q52905421)

9 May 2018

review article

1 reference

title

High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancer. (English)

1 reference

9 May 2018

author name string

Tallman MS

series ordinal

1

1 reference

9 May 2018

Gradishar WJ

series ordinal

2

1 reference

9 May 2018

publication date

1 January 1998

1 reference

9 May 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

9 May 2018

volume

42 Suppl

1 reference

9 May 2018

page(s)

S60-7

1 reference

9 May 2018

https://scigraph.springernature.com/pub.10.1007/s002800051081

exact match

0 references

cites work

Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Adjuvant systemic therapy for resectable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

The importance of dose intensity in chemotherapy of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

High-dose chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002800051081

21 January 2018

Identifiers

DOI

10.1007/S002800051081

1 reference

9 May 2018

PubMed ID

9750031

1 reference

9 May 2018